Liquid biopsy: an innovative and reliable method for detecting not only somatic, but also germline mutations in patients with colorectal and non-small cell lung carcinoma

References

• Shen Y, Shi R, Zhao R, et al. Clinical application of liquid biopsy in endometrial carcinoma. Med Oncol. 2023;40(3):1. doi: 10.1007/s12032-023-01956-4.
   Web of Science ®Google Scholar
• Veyseh M, Ricker C, Espenschied C, et al. Secondary germline finding in liquid biopsy of a deceased patient; case report and review of the literature. Front Oncol. 2018;8:259. doi: 10.3389/fonc.2018.00259.
   PubMed Web of Science ®Google Scholar
• Buglyó G, Styk J, Pös O, et al. Liquid biopsy as a source of nucleic acid biomarkers in the diagnosis and management of lynch syndrome. Int J Mol Sci. 2022;23(8):4284. doi: 10.3390/ijms23084284.
   PubMed Web of Science ®Google Scholar
• Esplin ED, Nielsen SM, Bristow SL, et al. Universal germline genetic testing for hereditary cancer syndromes in patients with solid tumor cancer. J Clin Oncol Precis Oncol. 2022;6:e2100516. doi: 10.1200/PO.21.00516.
   PubMed Web of Science ®Google Scholar
• Nikanjam M, Kato S, Kurzrock R. Liquid biopsy: current technology and clinical applications. J Hematol Oncol. 2022;15(1):131. doi: 10.1186/s13045-022-01351-y.
   PubMed Web of Science ®Google Scholar
• Chang CM, Lin KC, Hsiao NE, et al. Clinical application of liquid biopsy in cancer patients. BMC Cancer. 2022;22(1):413. doi: 10.1186/s12885-022-09525-0.
   PubMed Web of Science ®Google Scholar
• Polatoglou E, Mayer Z, Ungerer V, et al. Isolation and quantification of plasma cell-free DNA using different manual and automated methods. Diagnostics. 2022;12(10):2550. doi: 10.3390/diagnostics12102550.
   Web of Science ®Google Scholar
• Zhong L, He X, Zhang Y, et al. Relevance of methylenetetrahydrofolate reductase gene variants C677T and A1298C with response to fluoropyrimidine-based chemotherapy in colorectal cancer: a systematic review and meta-analysis. Oncotarget. 2018;9(58):31291–17. doi: 10.18632/oncotarget.24933.
   PubMedGoogle Scholar
• Raghubeer S, Matsha TE. Methylenetetrahydrofolate (MTHFR), the one-carbon cycle, and cardiovascular risks. Nutrients. 2021;13(12):4562. doi: 10.3390/nu13124562.
   PubMed Web of Science ®Google Scholar
• Imbard A, Benoist JF, Blom HJ. Neural tube defects, folic acid and methylation. Int J Environ Res Public Health. 2013;10(9):4352–4389. doi: 10.3390/ijerph10094352.
   PubMed Web of Science ®Google Scholar
• Kristensen MH, Pedersen PL, Melsen GV, et al. Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate synthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients. J Int Med Res. 2010;38(3):870–883. doi: 10.1177/147323001003800313.
   PubMed Web of Science ®Google Scholar
• Capitain O, Boisdron-Celle M, Poirier AL, et al. The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer. Pharmacogenomics J. 2008;8(4):256–267. doi: 10.1038/sj.tpj.6500476.
   PubMed Web of Science ®Google Scholar
• Dean L. Methylenetetrahydrofolate reductase deficiency. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kattman BL, Malheiro AJ, editors. Medical genetics summaries. Bethesda (MD): National Center for Biotechnology Information (US); 2012.
   Google Scholar
• Lee KH, Chang HJ, Han SW, et al. Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with Colon cancer. Cancer Chemother Pharmacol. 2013;71(4):843–851. doi: 10.1007/s00280-013-2075-3.
   PubMed Web of Science ®Google Scholar
• Fumagalli M, Lecca D, Abbracchio MP, et al. Pathophysiological role of purines and pyrimidines in neurodevelopment: unveiling new pharmacological approaches to congenital brain diseases. Front Pharmacol. 2017;8:941. doi: 10.3389/fphar.2017.00941.
   PubMed Web of Science ®Google Scholar
• Vogel WH, Minhas A, Baumrucker S. Dihydropyrimidine dehydrogenase deficiency: to screen or not to screen? J Adv Pract Oncol. 2020;11(1):68–73. doi: 10.6004/jadpro.2020.11.1.4.
   PubMedGoogle Scholar
• Božina N, Bilić I, Ganoci L, et al. DPYD polymorphisms c.496A > G, c.2194G > A and c.85T > C and risk of severe adverse drug reactions in patients treated with fluoropyrimidine-based protocols. Br J Clin Pharmacol. 2022;88(5):2190–2202. doi: 10.1111/bcp.15144.
   PubMed Web of Science ®Google Scholar
• Del Re M, Cinieri S, Michelucci A, et al. DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A > T: a comprehensive analysis in 1254 patients. Pharmacogenomics J. 2019;19(6):556–563. doi: 10.1038/s41397-019-0077-1.
   PubMed Web of Science ®Google Scholar
• Ruzzo A, Graziano F, Galli F, et al. Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk Colon cancer patients. Br J Cancer. 2017;117(9):1269–1277. doi: 10.1038/bjc.2017.289.
   PubMed Web of Science ®Google Scholar
• Iachetta F, Bonelli C, Romagnani A, et al. The clinical relevance of multiple DPYD polymorphisms on patients candidate for fluoropyrimidine based-chemotherapy. An Italian case-control study. Br J Cancer. 2019;120(8):834–839. doi: 10.1038/s41416-019-0423-8.
   PubMed Web of Science ®Google Scholar
• Madi A, Fisher D, Maughan TS, et al. Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy. Eur J Cancer. 2018;102:31–39. doi: 10.1016/j.ejca.2018.07.009.
   PubMed Web of Science ®Google Scholar
• Khushman M, Patel GK, Hosein PJ, et al. Germline pharmacogenomics of DPYD*9A (c.85T > C) variant in patients with gastrointestinal malignancies treated with fluoropyrimidines. J Gastrointest Oncol. 2018;9(3):416–424. doi: 10.21037/jgo.2018.02.03.
   PubMed Web of Science ®Google Scholar
• Schärer OD. Nucleotide excision repair in eukaryotes. Cold Spring Harb Perspect Biol. 2013;5(10):a012609. doi: 10.1101/cshperspect.a012609.
   PubMed Web of Science ®Google Scholar
• Nasrallah NA, Wiese BM, Sears CR. Xeroderma pigmentosum complementation group C (XPC): emerging roles in non-dermatologic malignancies. Front Oncol. 2022;12:846965. doi: 10.3389/fonc.2022.846965.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Cao J, Meng Y, et al. Overexpression of xeroderma pigmentosum group C decreases the chemotherapeutic sensitivity of colorectal carcinoma cells to cisplatin. Oncol Lett. 2018;15(5):6336–6344. doi: 10.3892/ol.2018.8127.
   PubMed Web of Science ®Google Scholar
• Sakano S, Hinoda Y, Sasaki M, et al. Nucleotide excision repair gene polymorphisms may predict acute toxicity in patients treated with chemoradiotherapy for bladder cancer. Pharmacogenomics. 2010;11(10):1377–1387. doi: 10.2217/pgs.10.106.
   PubMed Web of Science ®Google Scholar
• Blondy S, David V, Verdier M, et al. 5-Fluorouracil resistance mechanisms in colorectal cancer: from classical pathways to promising processes. Cancer Sci. 2020;111(9):3142–3154. doi: 10.1111/cas.14532.
   PubMed Web of Science ®Google Scholar
• Kim SY, Baek JY, Oh JH, et al. A phase II study of preoperative chemoradiation with tegafur-uracil plus leucovorin for locally advanced rectal cancer with pharmacogenetic analysis. Radiat Oncol. 2017;12(1):62. doi: 10.1186/s13014-017-0800-5.
   PubMedGoogle Scholar
• Panczyk M. Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years. World J Gastroenterol. 2014;20(29):9775–9827. doi: 10.3748/wjg.v20.i29.9775.
   PubMed Web of Science ®Google Scholar
• Griffith M, Mwenifumbo JC, Cheung PY, et al. Novel mRNA isoforms and mutations of uridine monophosphate synthetase and 5-fluorouracil resistance in colorectal cancer. Pharmacogenomics J. 2013;13(2):148–158. doi: 10.1038/tpj.2011.65.
   PubMed Web of Science ®Google Scholar
• Selo MA, Sake JA, Ehrhardt C, et al. Organic cation transporters in the lung-current and emerging (patho)physiological and pharmacological concepts. Int J Mol Sci. 2020;21(23):9168. doi: 10.3390/ijms21239168.
   PubMed Web of Science ®Google Scholar
• Samodelov SL, Kullak-Ublick GA, Gai Z, et al. Organic cation transporters in human physiology, pharmacology, and toxicology. Int J Mol Sci. 2020;21(21):7890. doi: 10.3390/ijms21217890.
   PubMed Web of Science ®Google Scholar
• Chen J, Wang L, Tong G, et al. The SLC22A2 gene is a determinant of hematological toxicity of oxaliplatin in patients with colorectal cancer. Int J Clin Pharmacol Ther. 2023;61(1):1–7. doi: 10.5414/CP204156.
   PubMed Web of Science ®Google Scholar
• Qian CY, Zheng Y, Wang Y, et al. Associations of genetic polymorphisms of the transporters organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), and ATP-binding cassette subfamily C member 2 (ABCC2) with platinum-based chemotherapy response and toxicity in non-small cell lung cancer patients. Chin J Cancer. 2016;35(1):85. doi: 10.1186/s40880-016-0145-8.
   PubMedGoogle Scholar
• Lindsey S, Langhans SA. Epidermal growth factor signaling in transformed cells. Int Rev Cell Mol Biol. 2015;314:1–41. doi: 10.1016/bs.ircmb.2014.10.001.
   PubMed Web of Science ®Google Scholar
• Liu W, Wu X, Zhang W, et al. Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines. Clin Cancer Res. 2007;13(22 Pt 1):6788–6795. doi: 10.1158/1078-0432.CCR-07-0547.
   PubMed Web of Science ®Google Scholar
• Tabernero J. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res. 2007;5(3):203–220. doi: 10.1158/1541-7786.MCR-06-0404.
   PubMed Web of Science ®Google Scholar
• De Pasquale MD, Crocoli A, Caldaro T, et al. Targeting epidermal growth factor receptor (EGFR) in pediatric colorectal cancer. Cancers. 2020;12(2):414. doi: 10.3390/cancers12020414.
   PubMed Web of Science ®Google Scholar
• Wang C, Li Y, Guan Y, et al. [Efficacy and influencing factors of immunotherapy combined with chemotherapy and bevacizumab in patients with non-small cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitors treatment failure]. Zhonghua Yi Xue Za Zhi. 2023;103(16):1210–1216. Chinese. doi: 10.3760/cma.j.cn112137-20221101-02275.
   PubMedGoogle Scholar
• Sui H, Fan ZZ, Li Q. Signal transduction pathways and transcriptional mechanisms of ABCB1/pgp-mediated multiple drug resistance in human cancer cells. J Int Med Res. 2012;40(2):426–435. doi: 10.1177/147323001204000204.
   PubMed Web of Science ®Google Scholar
• Chen Q, Lin W, Yang J, et al. Prognostic value of two polymorphisms, rs1045642 and rs1128503, in ABCB1 following taxane-based chemotherapy: a meta-analysis. Asian Pac J Cancer Prev. 2021;22(1):3–10. doi: 10.31557/APJCP.2021.22.1.3.
   PubMedGoogle Scholar
• Singh RR, Reindl KM. Glutathione S-transferases in cancer. Antioxidants. 2021;10(5):701. doi: 10.3390/antiox10050701.
   Web of Science ®Google Scholar
• Gonzalez-Haba E, García MI, Cortejoso L, et al. ABCB1 gene polymorphisms are associated with adverse reactions in fluoropyrimidine-treated colorectal cancer patients. Pharmacogenomics. 2010;11(12):1715–1723. doi: 10.2217/pgs.10.159.
   PubMed Web of Science ®Google Scholar
• McLeod HL, Sargent DJ, Marsh S, et al. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American gastrointestinal intergroup trial N9741. J Clin Oncol. 2010;28(20):3227–3233. doi: 10.1200/JCO.2009.21.7943.
   PubMed Web of Science ®Google Scholar
• Stoehlmacher J, Park DJ, Zhang W, et al. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer. 2004;91(2):344–354. doi: 10.1038/sj.bjc.6601975.
   PubMed Web of Science ®Google Scholar
• Joerger M, Huitema AD, Boot H, et al. Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy. Cancer Chemother Pharmacol. 2015;75(4):763–772. doi: 10.1007/s00280-015-2698-7.
   PubMed Web of Science ®Google Scholar
• Li Q, Damish AW, Frazier Z, et al. ERCC2 helicase domain mutations confer nucleotide excision repair deficiency and drive cisplatin sensitivity in muscle-invasive bladder cancer. Clin Cancer Res. 2019;25(3):977–988. doi: 10.1158/1078-0432.CCR-18-1001.
   PubMed Web of Science ®Google Scholar
• Manuguerra M, Saletta F, Karagas MR, et al. XRCC3 and XPD/ERCC2 single nucleotide polymorphisms and the risk of cancer: a HuGE review. Am J Epidemiol. 2006;164(4):297–302. doi: 10.1093/aje/kwj189.
   PubMed Web of Science ®Google Scholar
• Sullivan I, Salazar J, Majem M, et al. Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Lett. 2014;353(2):160–166. doi: 10.1016/j.canlet.2014.07.023.
   PubMed Web of Science ®Google Scholar
• Boige V, Mendiboure J, Pignon JP, et al. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. J Clin Oncol. 2010;28(15):2556–2564. doi: 10.1200/JCO.2009.25.2106.
   PubMedGoogle Scholar
• Huang MY, Fang WY, Lee SC, et al. ERCC2 2251A > C genetic polymorphism was highly correlated with early relapse in high-risk stage II and stage III colorectal cancer patients: a preliminary study. BMC Cancer. 2008;8(1):50. doi: 10.1186/1471-2407-8-50.
   PubMedGoogle Scholar
• Siu MK, Kong DS, Chan HY, et al. Paradoxical impact of two folate receptors, FRα and RFC, in ovarian cancer: effect on cell proliferation, invasion and clinical outcome. PLoS One. 2012;7(11):e47201. doi: 10.1371/journal.pone.0047201.
   PubMed Web of Science ®Google Scholar
• Huang L, Zhang T, Xie C, et al. SLCO1B1 and SLC19A1 gene variants and irinotecan-induced rapid response and survival: a prospective multicenter pharmacogenetics study of metastatic colorectal cancer. PLoS One. 2013;8(10):e77223. doi: 10.1371/journal.pone.0077223.
   PubMed Web of Science ®Google Scholar
• Pérez-Ramírez C, Cañadas-Garre M, Alnatsha A, et al. Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients. Pharmacogenomics J. 2019;19(2):164–177. doi: 10.1038/s41397-018-0014-8.
   PubMed Web of Science ®Google Scholar